Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference PR Newswire - Mon Feb 4, 6:00AM CST CMTX - Mon Feb 4, 6:00AM CST
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...
Has Curis (CRIS) Outpaced Other Medical Stocks This Year? Zacks Equity Research - Zacks Investment Research - Tue Jan 29, 8:30AM CST Zacks Equity Research - ZACKS - Tue Jan 29, 8:30AM CST
Is (CRIS) Outperforming Other Medical Stocks This Year?
Is Curis (CRIS) Outperforming Other Medical Stocks This Year? Zacks Equity Research - Zacks Investment Research - Thu Jan 10, 8:30AM CST Zacks Equity Research - ZACKS - Thu Jan 10, 8:30AM CST
Is (CRIS) Outperforming Other Medical Stocks This Year?
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire - Fri Jan 4, 3:00PM CST CMTX - Fri Jan 4, 3:00PM CST
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2019, the independent Compensation...
Aduro BioTech (ADRO) Looks Good: Stock Adds 7.7% in Session Zacks Equity Research - Zacks Investment Research - Fri Jan 4, 7:39AM CST Zacks Equity Research - ZACKS - Fri Jan 4, 7:39AM CST
Aduro BioTech (ADRO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture -- Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire - Fri Nov 30, 6:45AM CST CMTX - Fri Nov 30, 6:45AM CST
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dicerna Pharmaceuticals, Inc....
Curis to Present at the 60th Annual Meeting of the American Society of Hematology PR Newswire - Tue Nov 20, 9:45AM CST CMTX - Tue Nov 20, 9:45AM CST
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations...
Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit PR Newswire - Wed Nov 7, 3:05PM CST CMTX - Wed Nov 7, 3:05PM CST
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced upcoming presentations at the...
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates Zacks Equity Research - Zacks Investment Research - Thu Nov 1, 9:41AM CDT Zacks Equity Research - ZACKS - Thu Nov 1, 9:41AM CDT
Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Curis: 3Q Earnings Snapshot APAI - Thu Nov 1, 8:04AM CDT APAI - Thu Nov 1, 8:04AM CDT
LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Thursday reported a loss of $7.2 million in its third quarter.
Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018 PR Newswire - Tue Oct 23, 3:29PM CDT CMTX - Tue Oct 23, 3:29PM CDT
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that the Company will release...
Investor Expectations to Drive Momentum within Ormat Technologies, The Andersons, Freshpet, Curis, Ultra Clean, and Edge Therapeutics -- Discovering Underlying Factors of Influence GlobeNewswire - Tue Oct 23, 7:45AM CDT CMTX - Tue Oct 23, 7:45AM CDT
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ormat Technologies, Inc....
Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks Equity Research - Zacks Investment Research - Mon Oct 22, 11:08AM CDT Zacks Equity Research - ZACKS - Mon Oct 22, 11:08AM CDT
On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.
Curis (CRIS) Shares March Higher, Can It Continue? Zacks Equity Research - Zacks Investment Research - Fri Oct 19, 9:39AM CDT Zacks Equity Research - ZACKS - Fri Oct 19, 9:39AM CDT
As of late, it has definitely been a great time to be an investor in Curis, Inc. (CRIS).
Curis: 1Q Earnings Snapshot APAI - Thu May 3, 7:58AM CDT APAI - Thu May 3, 7:58AM CDT
LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Thursday reported a loss of $10.7 million in its first quarter.
Curis Reports First Quarter 2018 Financial Results PR Newswire - Thu May 3, 6:00AM CDT CMTX - Thu May 3, 6:00AM CDT
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today reported its financial results...
Curis to Release First Quarter 2018 Financial Results and Hold Conference Call on May 3, 2018 PR Newswire - Thu Apr 26, 6:00AM CDT CMTX - Thu Apr 26, 6:00AM CDT
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire - Fri Apr 6, 6:00AM CDT CMTX - Fri Apr 6, 6:00AM CDT
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that...
Investor Expectations to Drive Momentum within Atrion, Curis, Independence Contract Drilling, Utah Medical Products, FutureFuel, and Opiant Pharmaceuticals -- Discovering Underlying Factors of Influence GlobeNewswire - Tue Apr 3, 7:01AM CDT CMTX - Tue Apr 3, 7:01AM CDT
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Atrion Corporation (NASDAQ:ATRI),...
Biotech Stocks' Research Reports Released on CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics PR Newswire - Wed Mar 21, 6:10AM CDT CMTX - Wed Mar 21, 6:10AM CDT
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on CRMD, CRIS, CYCC, and CBAY which can be accessed for free by signing up to www.wallstequities.com/registration....
